Cargando…

Hot needles can confirm accurate lesion sampling intraoperatively using [(18)F]PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted PET is increasingly used for staging prostate cancer (PCa) with high accuracy to detect significant PCa (sigPCa). [(68) Ga]PSMA-11 PET/MRI-guided biopsy showed promising results but also persisting limitation of sampling error, due to impai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferraro, Daniela A., Laudicella, Riccardo, Zeimpekis, Konstantinos, Mebert, Iliana, Müller, Julian, Maurer, Alexander, Grünig, Hannes, Donati, Olivio, Sapienza, Marcelo T., Rueschoff, Jan H., Rupp, Niels, Eberli, Daniel, Burger, Irene A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560591/ https://www.ncbi.nlm.nih.gov/pubmed/34725726 http://dx.doi.org/10.1007/s00259-021-05599-3

Ejemplares similares

Diagnostic performance of (68)Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study
por: Ferraro, Daniela A., et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement
por: Ferraro, Daniela A., et al.
Publicado: (2022)

Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
por: Maurer, Alexander, et al.
Publicado: (2022)

Focal unspecific bone uptake on [(18)F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging
por: Grünig, Hannes, et al.
Publicado: (2021)

What’s behind (68)Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
por: Rüschoff, Jan H., et al.
Publicado: (2021)

Improved oncological outcome after radical prostatectomy in patients staged with (68)Ga-PSMA-11 PET: a single-center retrospective cohort comparison
por: Ferraro, Daniela A., et al.
Publicado: (2020)

Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features?
por: Laudicella, Riccardo, et al.
Publicado: (2023)

Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET
por: Ferraro, Daniela A., et al.
Publicado: (2020)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual Reproducibility
por: Mamlins, E., et al.
Publicado: (2022)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

Non-prostate uptake on (18)F-PSMA-1007 PET/CT: a case of myeloma
por: Veerasuri, Sowmya, et al.
Publicado: (2020)

Dose-reduced [(18)F]PSMA-1007 PET is feasible for functional imaging of the renal cortex
por: Valind, Kristian, et al.
Publicado: (2021)

[(18)F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue
por: Di Iorio, Valentina, et al.
Publicado: (2021)

(18)F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis
por: Ferrari, Matteo, et al.
Publicado: (2021)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

Comparison of the PI-RADS 2.1 scoring system to PI-RADS 2.0: Impact on diagnostic accuracy and inter-reader agreement
por: Hötker, Andreas M., et al.
Publicado: (2020)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Optimization of [(18)F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
por: Trägårdh, Elin, et al.
Publicado: (2020)

[(18)F]PSMA‐1007 renal uptake parameters: Reproducibility and relationship to estimated glomerular filtration rate
por: Valind, Kristian, et al.
Publicado: (2022)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

The value of (18)F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
por: Hong, Jun-jie, et al.
Publicado: (2020)

Automated [(18)F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination
por: Naka, Sadahiro, et al.
Publicado: (2020)

Diagnostic Role of (18)F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
por: Awenat, Salam, et al.
Publicado: (2021)

Risk of metastatic disease using [(18)F]PSMA-1007 PET/CT for primary prostate cancer staging
por: Chikatamarla, Venkata Avinash, et al.
Publicado: (2021)

An exploratory study of unexplained concentration of (18)F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging
por: Dang, Jun, et al.
Publicado: (2023)

Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
por: Hoberück, Sebastian, et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer
por: Fassbind, Saskia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dtgen2dem6fv1k7hu85j0u9dgd